Job title: Associate Director, Immuno-Oncology
David DiLillo is a Senior Staff Scientist in the Immuno-Oncology department at Regeneron Pharmaceuticals in New York, where he leads a team investigating novel T cell-retargeting technologies. His team is responsible for IND-enabling as well as mechanistic in vitro and in vivo studies using Regeneron’s unique bispecific antibody platform to identify immune-targeted therapeutics to treat liquid and solid tumors. His team also actively investigates chimeric antigen receptor (CAR) T cell biology in similar model systems. Dr. DiLillo holds a Ph.D. in Immunology from Duke University, where he studied non-classical B cell effector functions, and he completed his postdoctoral studies in Fc-receptor biology at the Rockefeller University.
Benchmarking T Cell-Redirecting Therapies for Cancer: Comparing CD3Bispecifics and CAR T Cells 4:00 pm
Two competing platforms exist for redirecting T cells to recognize and kill tumors: Bispecific antibodies and chimeric antigen receptor (CAR) T cells We have developed preclinical in vitro and in vivo models to mechanistically compare these two technologies and will discuss our findings as well as the clinical implicationsRead more
day: Day Two
Chair’s Closing Remarks & End of Day One 5:05 pm
day: Day One